REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by HI, ...

Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program REDWOOD CITY, ...

Topline data were announced from a phase 3 trial evaluating ersodetug in patients aged 3 months to 45 years with congenital hyperinsulinism.

If you have type 1 or type 2 diabetes, your blood sugar can fall to dangerously low levels without you knowing it. Learn hypoglycemia unawareness symptoms and treatment.

Risk factors for hypoglycemia include mismatch of insulin timing, amount or type of carbohydrate intake, taking oral secretagogues without adequate carbohydrate intake, history of severe hypoglycemia, ...

Hypoglycemia occurs when blood sugar (glucose) levels fall below 70 milligrams per deciliter, creating a medical emergency that requires immediate treatment. The condition affects people with and ...

Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in ...

"FDA's granting of Orphan Drug Designation is a recognition of the serious unmet need patients with tumor hyperinsulinism face and validates the potential significant benefit that ersodetug can ...